Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06560905 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

Study acronym: PPPIMS
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 1, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date changed from estimate of Sep 1, 2024 to Mar 11, 2025
    • Study sites: 0 to 1
    • Primary completion date: Aug 1, 2025 to Dec 31, 2025
    • Study completion date: Dec 15, 2025 to Dec 31, 2025
  2. Study description revisedv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.
Trial Details
NCT Number NCT06560905
Lead Sponsor Royal Marsden NHS Foundation Trust
Conditions
(from sponsor)		 Malignant Melanoma
Related terms Melanoma
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov